A Study of Participants With Advanced Prostate Cancer in Canada

Titre officiel

A Multicentre Cohort Study of Patients With Advanced Prostate Cancer in Canada

Sommaire:

Cette étude vise à documenter l’évolution du cancer de la prostate avancé au Canada en matière de progression de la maladie, de traitement en situation réelle et de prise en charge des patients.

Description de l'essai

Primary Outcome:

  • Time to Prostate Specific Antigen (PSA) Progression
  • Time to Radiographic Evidence of Disease Progression
  • Time to Skeletal-Related Events
  • Time to Death
  • Number of Participants with Different Primary Causes of Death
  • Time to Progression from mCSPC to mCRPC in Participants with mCSPC
  • Time from Biochemical Recurrence (BCR) to Nonmetastatic Castrate-Resistant Prostate Cancer (nmCRPC) and nmCRPC to mCRPC
  • Number of Participants with PSA Testing from BCR to nmCRPC and nmCRPC to mCRPC, in Participants with mCRPC
  • PSA Level at Start of Androgen Deprivation Therapy (ADT) in Participants with mCRPC
  • PSA Doubling Time (PSAdt) at the Detection of Castration Resistance in Participants with mCRPC
  • Time to Initiation of Subsequent Prostate Cancer Treatment
  • Duration of Each Therapy
  • Percentage of Participants Receiving Chemotherapy, Other Drug Treatments, or no Drug Treatment
  • Time to Treatment Initiation
  • Time to Dose Modification
  • Number of Participants who Switch the Treatment
  • Number of Participants who Discontinued the Treatment
  • Most Common Sequences for Lines of Therapy in Participants with mCRPC
  • Number of Participants Retreated with Docetaxel in Participants with mCRPC
  • Percentage of Participant with Radiographic Imaging Modality
  • Number of Days Hospitalized for Prostate Cancer or Treatment of Prostate Cancer
  • Number of Visits to Emergency Department for Prostate Cancer or Treatment of Prostate Cancer
  • Number of Outpatient Visits to Specialists Involved in Management of Prostate Cancer
  • Charlson Comorbidity Index Score

Voir cet essai sur ClinicalTrials.gov

Intéressé(e) par cet essai?

Imprimez cette page et apportez-la chez votre médecin pour discuter de votre admissibilité à cet essai et des options de traitement. Seul votre médecin peut vous recommander pour un essai clinique.

Ressources

Société canadienne du cancer

Ces ressources sont fournies en partenariat avec Société canadienne du cancer